Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

12.8%

6 terminated/withdrawn out of 47 trials

Success Rate

85.4%

-1.1% vs industry average

Late-Stage Pipeline

64%

30 trials in Phase 3/4

Results Transparency

6%

2 of 35 completed trials have results

Key Signals

3 recruiting2 with results6 terminated

Enrollment Performance

Analytics

Phase 3
26(55.3%)
Phase 2
16(34.0%)
Phase 4
4(8.5%)
Phase 1
1(2.1%)
47Total
Phase 3(26)
Phase 2(16)
Phase 4(4)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (47)

Showing 20 of 47 trials
NCT06596252Phase 3Recruiting

Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE

Role: lead

NCT05621811Phase 2Completed

Different Doses of Naronapride vs. Placebo in Gastroparesis

Role: lead

NCT07298343Phase 2Recruiting

Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease

Role: lead

NCT06886360Phase 3Not Yet Recruiting

Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC)

Role: lead

NCT03872921Phase 3Active Not Recruiting

norUrsodeoxycholic Acid vs Placebo in PSC

Role: lead

NCT05305599Phase 2Completed

Different Doses of ZED1227 vs. Placebo in NAFLD

Role: lead

NCT05083390Phase 2Recruiting

Norursodeoxycholic Acid vs. Placebo in NASH

Role: lead

NCT05488405Phase 2Completed

Mesalazine Oral Suspension in Active Eosinophilic Esophagitis

Role: lead

NCT02493335Phase 3Completed

Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis

Role: lead

NCT03844932Phase 2Terminated

A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis

Role: collaborator

NCT02142634Phase 3Completed

Budesonide for Induction of Remission in Incomplete Microscopic Colitis

Role: lead

NCT00746486Phase 3Terminated

Ursodeoxycholic Acid Plus Budesonide Versus Ursodeoxycholic Acid Alone in Primary Biliary Cirrhosis (PBC)

Role: lead

NCT02280629Phase 3Completed

Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2)

Role: lead

NCT01882088Phase 4Completed

Phase IV Study of the Impact of Dietary Fibers on Symptoms and Esophageal Motility in Patients With Non-erosive GERD

Role: collaborator

NCT01510860Phase 4Completed

Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis

Role: lead

NCT00529009Phase 1Completed

Pharmacokinetic Investigation of UDCA in Bile and Serum

Role: lead

NCT01966783Phase 2Completed

Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis

Role: lead

NCT00838214Phase 2Completed

Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis

Role: lead

NCT01208922Phase 3Completed

Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea

Role: lead

NCT01847664Phase 2Completed

Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in Acute Uncomplicated Diverticulitis

Role: lead